维普中文期刊产品整合服务
43篇 您的检索式:作者名="Mayer MD"
    题名 作者 年代 出处 被引量
1糖尿病诊断:界定与替换显示文摘几乎所有人群血糖浓度都是单峰分布模式,因此没有明确的分界点来确定糖尿病的诊断。老的标准为空腹血糖浓度(fasting plasma glucose,FPG)≥140mg/dl或者口服葡萄糖耐量试验(oral glucose tolerance test,OGTT)2h血糖浓度≥200mg/dl,选择这样的标准是因为超过这些血糖值的部分病人3-8年后发生了视网膜病变。糖尿病诊断和分类专家委员会将FPG诊断标准降低到126mg/dl,使其和OGTT2h血糖浓度200mg/dl相当。过量的糖化蛋白产物在糖尿病微血管和神经并发症的病例机制中起重要作用。60%的新队列糖尿病病人,其FPG在126mg/dl-139mg/dl,且糖化血红蛋白(HbAIC)水平正常;35%的病人未用药物治疗之前就已经达到美国糖尿病学会(ADA)推荐的目标HbAl<7%。糖尿病病人维持HbAlC水平在7%以下的,6-10年之后几乎极少或者不发生视网膜病变和肾病变,或者巳有的病变不再进展。糖尿病的诊断对保险(生命和医疗),就业、社会和心理花费等均具有负面影响。此外,在糖尿病新的人群中,不论是诊断为糖尿病还是空腹血糖受损都可先予以非药物治疗,因此,以我的观点,FPG血糖标准仍应维持≥140mg/dl,除非有过量的糖化产物即HbAlC≥7%(假定上限值为6%)。依据HbAlC水平升高来诊断FPG<140mg/dl的糖尿病是和老的选择发生视网膜病变的葡萄糖浓度的诊断标准是一致的,因此建议选择性地使用初期FPG浓度加上以后糖化血红蛋白水平的流程来诊断糖尿病。学习目的:了解新推荐的糖尿病诊断中空腹血糖(FPG)标准的变化,以及这一变化导致的糖尿病“新队列”的重要意义。复习糖尿病并发症和FPG水平增高以及糖化血红蛋白(HbAlC)之间的关系。考虑临床实践中对FPG和HbAlC基本治疗可行性以及何种检测对“新队列”病人合适。Mayer B Davidson,MD 李玉秀 2001世界医学杂志2001,5,10:3
2Accuracy of Determining Nodal Negativity in Colorectal Cancer on the Basis of the Number of Nodes Retrieved on Resection显示文摘Natalie E. Joseph MD Elin R. Sigurdson MD PhD Alexandra L. Hanlon PhD Hao Wang MS Robert J. Mayer MD John S. MacDonald MD Paul J. Catalano ScD Daniel G. Haller MD 2003Annals of Surgical Oncology2003,,3:2
3An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus显示文摘Mayer B Davidson MD Anne L Peters MD 1997The American Journal of Medicine1997,,1:1
4Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumer wfficacy of doxorubicin 显示文摘Balazsovits JAE Mayer LD Bally MD 1989Cancer Chemother Pharmacol1989,23,:1
5Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhi- bitor ofxanthine oxidase in subjects with renal impairment 显示文摘Mayer MD Khosravan R Vemillet L 2005Am J Ther2005,12,1:1
6Genetics and heritability of coronary artery disease and myocardial infarction显示文摘Dr. Bj?rn Mayer MD Jeanette Erdmann PhD Heribert Schunkert MD 2007Clinical Research in Cardiology2007,,1:1
7Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfu- sion:possible role of heine as both promotor of tissue damage and regulator of HSP32 显示文摘Maines MD Mayer RD Ewing JF 1993J Pharmacol Exp Ther1993,264,1:1
8Induction of intercellular adhesion molecule-1 and sE-selectin mRNA in heart and skeletal muscle of pediatric patients undergoing cardiopulmonary bypass显示文摘 John E Mayer MD 1994Thorac Cardiovasc Sirg1994,107,:1
9Derilesional blood flow and edema formation in acute intracerebral hemorrhage:ASPECT Study显示文摘 Mayer MD Lignelli A 1998Stroke1998,29,:1
10Cost Effectiveness of statin therapy for the primary prevention of major coronary evcnta in individuals with type2 diabetes显示文摘Michael Brandle MD Mayer B Davldson 0,,:1
11Induction of Kidney heine oxygenase-1 (HSP32) mRNA and protein by ischemic-reperfusion possible role of heine as both promotor of tissue damage and regulator of HSP32显示文摘Maines MD Mayer RD Ewing JF 1993J Pharmacol Exp Ther1993,264,:1
12Burstein, MD, PHI), Chemotherapy for metastatic Breastcancer 显示文摘Erical Mayer MD MPH Hardd J 2007Hematol Oncol Clin NAMZ2007,,:1
13Ethoxy-,pentoxy-and benzy-loxyphenoxazones and homologues:a series of substratesto distinguish between different induced cytochromes P-450显示文摘Burke MD Thompson S Elcombe CR Halpert J Haaparanta T Mayer RT 1985Biochem Pharmacol1985,34,18:1
14Accuracy of Determining Nodal Negativity in Colorectal Cancer on the Basis of the Number of Nodes Retrieved on Resection显示文摘Natalie E. Joseph MD Elin R. Sigurdson MD PhD Alexandra L. Hanlon PhD Hao Wang MS Robert J. Mayer MD John S. MacDonald MD Paul J. Catalano ScD Daniel G. Haller MD 2003Annals of Surgical Oncology2003,,3:1
15How do we diagnose diabetes and measure blood glueose control显示文摘Mayer B Davidson MD 2001Diaberess Petrum2001,14,:1
16Pharma- cokinetics and pharmacodynamics of febuxostat, a new selective nonpurine inhibitor of xanthine oxidase, in subjects with renal impairment显示文摘MAYER MD KHOSRAVAN R VERNILLET L 2005Am J Ther2005,12,1:1
17The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodyaamics, and safety of febnxostat, a novel non- purine selective inhibitor of xanthine oxidase 显示文摘KHOSRAVAN R GRABOWSKI BA MAYER MD 2006J Clin Pharmacol2006,46,1:1
18Pharmacokinetics and pharmacodynamics of febuxostat, a new non-pufine selective inhibitor of xanthine oxidase in subjects with renal impairment显示文摘MAYER MD KHOSRAVAN R VERNILLET L 2005Am J Ther2005,12,1:1
19Pure global acalculia following a left subangular lesion显示文摘Martory MD Mayer E Pegna AJ 2003Neurocase2003,,4:1
20Toward a global phylogeny of the Brassicaceae显示文摘Bailey CD Koch MA Mayer M Mummenhoff K O'Kane SL Warwick SI Windham MD Al-Shehbaz IA 0,,:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费